Linsitinib (OSI-906)

製品コードS1091

Linsitinib (OSI-906)化学構造

分子量(MW):421.49

Linsitinib (OSI-906)は一種の選択性的なIGF-1R阻害剤で、無細胞実験で、IC50値が35 nMです。OSI-906 (Linsitinib)はInsRを適合に抑制して、このIC50値が75 nMになリますが、Abl、ALK、BTK、EGFR、FGFR1/2とPKA等に抑制活性を表しません。臨床3期。

サイズ 価格(税別) 在庫  
JPY 31540.00 あり
JPY 28220.00 あり
JPY 44820.00 あり
JPY 119520.00 あり

カスタマーフィードバック(4)

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

製品安全説明書

IGF-1R阻害剤の選択性比較

生物活性

製品説明 Linsitinib (OSI-906)は一種の選択性的なIGF-1R阻害剤で、無細胞実験で、IC50値が35 nMです。OSI-906 (Linsitinib)はInsRを適合に抑制して、このIC50値が75 nMになリますが、Abl、ALK、BTK、EGFR、FGFR1/2とPKA等に抑制活性を表しません。臨床3期。
ターゲット
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外試験

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M37qN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmG5TWM2OD1yLkCyPFA3KM7:TR?= M2\WV3NCVkeHUh?=
KS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr1SmJIUUN3ME2wMlA{QDN3IN88US=> NYLROXl[W0GQR1XS
TE-11 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEe4NlIh|ryP NHrwfZVUSU6JRWK=
EW-1 MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfpSGFKSzVyPUCuNFg2QDVizszN NV;CN4d6W0GQR1XS
HMV-II MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrJS3VRUUN3ME2wMlA5QDR4IN88US=> NUfRU|JkW0GQR1XS
COLO-205 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLZTWM2OD1yLkGwOFU1KM7:TR?= M1i5[nNCVkeHUh?=
ES1 MnGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMUC2PVYh|ryP M3vBbnNCVkeHUh?=
GDM-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLDUJQxUUN3ME2wMlE{Pjd{IN88US=> NF3IcopUSU6JRWK=
ML-2 Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMUW4PVYh|ryP MWTTRW5ITVJ?
Saos-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\zeI42UUN3ME2wMlE3PTJ4IN88US=> NIjTWoxUSU6JRWK=
NCI-H1355 NXTiV3NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMUixN|Uh|ryP NEL6dGJUSU6JRWK=
G-401 NE\hd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMUiyN{DPxE1? NHSxRlRUSU6JRWK=
EW-16 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TmdWlEPTB;MD6xPFc4PyEQvF2= MVnTRW5ITVJ?
EW-7 NVjkcYVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMUi4PFEh|ryP NGr1WpJUSU6JRWK=
NCI-H727 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMUm3PVQh|ryP NH\wdmpUSU6JRWK=
LCLC-97TM1 NVW3cVV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMkC5OVUh|ryP MXHTRW5ITVJ?
NCI-H650 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LNUGlEPTB;MD6yNVM5PCEQvF2= NHvMZ5BUSU6JRWK=
NCI-H2122 NGS5enJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rpOWlEPTB;MD6yN|I6QSEQvF2= MWfTRW5ITVJ?
SK-N-DZ NIO0[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfkTWM2OD1yLkKzOlk5KM7:TR?= NYXreVdRW0GQR1XS
HT-29 M17JU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1npZWlEPTB;MD6yOFI1QCEQvF2= M37n[nNCVkeHUh?=
LB771-HNC Ml\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nYdGlEPTB;MD6yOVkyPSEQvF2= NULqTGpTW0GQR1XS
HT-144 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPK[YdnUUN3ME2wMlI3OTlzIN88US=> NXLQXHM4W0GQR1XS
LAN-6 M3TzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMk[zOFgh|ryP NEXNfYFUSU6JRWK=
EW-18 NYnFe5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;ZSoZTUUN3ME2wMlI4ODBzIN88US=> M3vXS3NCVkeHUh?=
LS-1034 M4PuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlWwTWM2OD1yLkK3NVMzKM7:TR?= MVXTRW5ITVJ?
EW-11 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMki0N|Ih|ryP M3;SfnNCVkeHUh?=
SNU-C1 M3vQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vyd2lEPTB;MD6yPVMyOyEQvF2= M{Lrd3NCVkeHUh?=
RS4-11 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nhXWlEPTB;MD6zN|c2QCEQvF2= NH\5XHdUSU6JRWK=
ES4 NHm3bnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorWTWM2OD1yLkSxNFM5KM7:TR?= MojvV2FPT0WU
COLO-320-HSR MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNEGzOlgh|ryP NXzmendbW0GQR1XS
NB10 MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe1eW1KSzVyPUCuOFU1OzdizszN NULoN|JTW0GQR1XS
BFTC-905 NHHWbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHroVpdKSzVyPUCuOFY4PThizszN NF2xVXlUSU6JRWK=
A375 MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwNEe2NVch|ryP MmD1V2FPT0WU
SJRH30 M4PUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwNUC4NlIh|ryP Mn\kV2FPT0WU
NOS-1 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7USW1ZUUN3ME2wMlUzOjZ5IN88US=> Mo\qV2FPT0WU
SIG-M5 NYnpT5BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PI[2lEPTB;MD61N|U2PyEQvF2= Ml;BV2FPT0WU
DOK MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNUW2JO69VQ>? NGLhWVBUSU6JRWK=
NB69 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nrTmlEPTB;MD61PFI2PyEQvF2= Mom3V2FPT0WU
SK-NEP-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOxcGZKSzVyPUCuOlAzOzZizszN MVvTRW5ITVJ?
SK-MM-2 M4rlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrySpJUUUN3ME2wMlY2PDlzIN88US=> NIH2NppUSU6JRWK=
NCI-H358 M1LIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LM[GlEPTB;MD62O|A5OiEQvF2= NW\ud2V1W0GQR1XS
RH-1 NVXV[phOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXmwZ5U1UUN3ME2wMlc1QDV7IN88US=> MXfTRW5ITVJ?
NH-12 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jreWlEPTB;MD63OlA1PiEQvF2= M{TrW3NCVkeHUh?=
TE-12 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm3dWtQUUN3ME2wMlc3PDh4IN88US=> MV\TRW5ITVJ?
COLO-668 Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPiR|VKSzVyPUCuPFQ3PjZizszN NGjpbndUSU6JRWK=
PANC-08-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n5Z2lEPTB;MD64OlM4PyEQvF2= M3ewUXNCVkeHUh?=
HCC2998 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX6TWM2OD1yLki4NlY{KM7:TR?= NF7jOJdUSU6JRWK=
ABC-1 NGD4dnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwOUCzOVIh|ryP M3zJO3NCVkeHUh?=
ES6 M4nXSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwOUGwOlYh|ryP NXXBWFRIW0GQR1XS
SNU-387 M4HCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHO0[lJKSzVyPUCuPVk{QTNizszN MYPTRW5ITVJ?
CMK M4LkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TwSGlEPTB;MD65PVkzQSEQvF2= NILs[pRUSU6JRWK=
SJSA-1 M1:2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwMEO2OVMh|ryP NH7EbmFUSU6JRWK=
SIMA NHnGUo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vPT2lEPTB;MT6wOlgzPSEQvF2= NFHGVo9USU6JRWK=
ES3 NF\CTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwMUKyPVch|ryP MmPTV2FPT0WU
IGROV-1 NFHqe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfQc|dKSzVyPUGuNVU1PDRizszN MXTTRW5ITVJ?
MEL-JUSO NYTJTpBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTRcItKSzVyPUGuNVU4PTlizszN NWT6[pZ7W0GQR1XS
T84 NGLTfFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwMkC5NVQh|ryP NEC3O5dUSU6JRWK=
CAL-85-1 NVvoXGNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TaNmlEPTB;MT6yN|E{QCEQvF2= MnnsV2FPT0WU
RD NWO3fFViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwMk[0OVUh|ryP MVjTRW5ITVJ?
TE-8 NWHjUlNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwM{G0OlIh|ryP NXvC[IFwW0GQR1XS
L-363 NH3iV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwM{SyNFgh|ryP M4DQW3NCVkeHUh?=
EKVX NHPHellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDxTHVKSzVyPUGuN|Q2PjhizszN NXnNRXlVW0GQR1XS
SK-MEL-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYftSIZWUUN3ME2xMlQ5PTV4IN88US=> MUfTRW5ITVJ?
TGBC24TKB NIDGR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\BdnZNUUN3ME2xMlUxOTl|IN88US=> NE\0bmpUSU6JRWK=
NCI-H1770 NHHkR2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF71W5JKSzVyPUGuOVEyOTNizszN NV\obY9LW0GQR1XS
HuH-7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXuTWM2OD1zLk[wNFk5KM7:TR?= MmPPV2FPT0WU
HL-60 M4nnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TTc2lEPTB;MT62OlkzQCEQvF2= NEfkfmRUSU6JRWK=
TE-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwN{C5OFUh|ryP NI\i[VFUSU6JRWK=
LC-2-ad NUPCe2o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33IfGlEPTB;MT63N|g5PyEQvF2= NInIZYZUSU6JRWK=
LB647-SCLC NYDabpJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrOUWtEUUN3ME2xMlc3PTh|IN88US=> M17XcHNCVkeHUh?=
NCI-H2171 NUnaZZc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3qTWM2OD1zLke3O|E3KM7:TR?= NF;wXm5USU6JRWK=
SK-PN-DW M3ntTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[weZBKSzVyPUGuPVEzQThizszN MnrjV2FPT0WU
MC-IXC NXPGd|ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwOUi5PEDPxE1? MoHyV2FPT0WU
LS-513 M1nCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LifmlEPTB;Mj6wOVMxPSEQvF2= MWDTRW5ITVJ?
EW-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILkOHBKSzVyPUKuNFk5PDRizszN NXzjPGZKW0GQR1XS
OPM-2 M3\3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFva[FFKSzVyPUKuNVAzKM7:TR?= NHPPR2VUSU6JRWK=
LP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjBXFNKSzVyPUKuNlU5ODdizszN MlPuV2FPT0WU
LU-134-A NULQXYZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwMke3JO69VQ>? NUj6emlTW0GQR1XS
CP66-MEL NF74XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrwOHBLUUN3ME2yMlI6ODF2IN88US=> MXzTRW5ITVJ?
HCC1143 NXO2SpJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnToTWM2OD1{LkS1N|Y5KM7:TR?= NVTJVmRxW0GQR1XS
LOXIMVI MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTJwNkCyNUDPxE1? MXnTRW5ITVJ?
TE-10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXsTWM2OD1{LkewPFM5KM7:TR?= NUjLPYJ3W0GQR1XS
NCI-H1882 M2fveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXRTJJKSzVyPUKuO|UzOjdizszN MUPTRW5ITVJ?
CHP-126 NYH4fYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP3RWZKSzVyPUKuO|Y{OTdizszN MlPHV2FPT0WU
NCI-H1623 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJwOUKwNlQh|ryP NF3seodUSU6JRWK=
GB-1 NX7FRVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5TWM2OD1{LkmzOFA1KM7:TR?= NHvoS4dUSU6JRWK=
RCC10RGB NXv5SXIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfY[25KSzVyPUKuPVUzQDFizszN MWnTRW5ITVJ?
NCI-H2141 M3PZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJwOU[4PVYh|ryP NUPhUZd7W0GQR1XS
GI-ME-N NInl[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXPU3FKSzVyPUOuNFA2PjVizszN NIrCUGJUSU6JRWK=
NCI-H526 NXHTb45XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\XWldQUUN3ME2zMlA1ODh3IN88US=> M1zZXXNCVkeHUh?=
NCI-H747 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm2TWM2OD1|LkC0PVkzKM7:TR?= M37xWXNCVkeHUh?=
SNU-423 MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNwMkCzNVMh|ryP M3vyVnNCVkeHUh?=
A427 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[4TWM2OD1|LkK1Olk6KM7:TR?= M4nHfnNCVkeHUh?=
CAL-12T M3rBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TtR2lEPTB;Mz60NFcyOyEQvF2= MlfRV2FPT0WU
LU-99A M4rqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHxTWM2OD1|LkS3NVA2KM7:TR?= M4iwTnNCVkeHUh?=
MS-1 NYXES4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfSWY57UUN3ME2zMlU{PDJ7IN88US=> NGq0NZdUSU6JRWK=
SK-LU-1 M1XwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwN{[yPVUh|ryP MWLTRW5ITVJ?
SW837 MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwN{[zN|Mh|ryP MVTTRW5ITVJ?
ES8 NXnr[5I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLKVGtKSzVyPUOuPFM5PzdizszN MXvTRW5ITVJ?
MZ2-MEL M4ruXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\zXmlEPTB;Mz65NlA5PiEQvF2= NGLXbnhUSU6JRWK=
TGW MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4niTmlEPTB;ND6wNVMyOSEQvF2= MWXTRW5ITVJ?
GP5d MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni2TWM2OD12LkC1N|YzKM7:TR?= M4LPT3NCVkeHUh?=
BB49-HNC M4m3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2zdpFKSzVyPUSuNVUzOTNizszN MmPCV2FPT0WU
NB13 NVvERm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3DNFNKSzVyPUSuNlY5QDdizszN M2jhc3NCVkeHUh?=
NTERA-S-cl-D1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTRwMki2NVUh|ryP NULrU3VoW0GQR1XS
NCI-H1648 NX;qOYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPBPXdkUUN3ME20MlI6QDF7IN88US=> NFXQdllUSU6JRWK=
LCLC-103H NGSzSHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfuZZhKSzVyPUSuN|IyQTVizszN M1HzeXNCVkeHUh?=
LS-411N NFvodWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7pc49sUUN3ME20MlQ1QDh3IN88US=> MY\TRW5ITVJ?
NCI-H1092 NELHbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjYc|dKSzVyPUSuOFU3QDdizszN NGixWFdUSU6JRWK=
PANC-10-05 NXHkcmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:yUlFjUUN3ME20MlY6QDRizszN M1Thb3NCVkeHUh?=
DK-MG MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[y[mg5UUN3ME20MlgxQTN|IN88US=> NUHYVo1jW0GQR1XS
OVCAR-5 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvNWG1KSzVyPUSuPFEzOjZizszN NYLlW|gyW0GQR1XS
CAL-39 NHPOOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnJenRKSzVyPUSuPFc3PyEQvF2= Mn2yV2FPT0WU
TE-441-T M3XFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TvfWlEPTB;ND65NFU{PyEQvF2= M2\2d3NCVkeHUh?=
MOLT-16 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DRNWlEPTB;ND65OVI2OyEQvF2= NFm3R4hUSU6JRWK=
MCF7 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\pcGlEPTB;NT6xOFUyPyEQvF2= NIXFb5pUSU6JRWK=
CAPAN-1 NGL3UmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\ETnBKSzVyPUWuNlU4ODdizszN MWnTRW5ITVJ?
PSN1 M2rzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIWx[GNKSzVyPUWuNlczOzVizszN MoLIV2FPT0WU
NCI-H292 NEKyOYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nHZWlEPTB;NT6zNFA1PCEQvF2= NHjBSnhUSU6JRWK=
CPC-N NIfV[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnENZR3UUN3ME21MlM6PDF7IN88US=> NYS1cotLW0GQR1XS
DoTc2-4510 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D3SWlEPTB;NT60OVM4OSEQvF2= M4\mbXNCVkeHUh?=
LB1047-RCC MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTVwNUW5N|Mh|ryP MXvTRW5ITVJ?
MHH-ES-1 M1vNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTVwNUm5NFch|ryP MkjBV2FPT0WU
NMC-G1 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\ZTGlEPTB;NT63NFIzPyEQvF2= NGXHe3NUSU6JRWK=
SW1710 NGDpcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLjTIVUUUN3ME21Mlc1PzVzIN88US=> NHrn[XBUSU6JRWK=
YAPC M3e5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnCTWM2OD13Lke2NlAyKM7:TR?= NFvXTmVUSU6JRWK=
22RV1 Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXiW|ZyUUN3ME21MlgxODF7IN88US=> Mom5V2FPT0WU
COLO-679 M2jXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH4cXllUUN3ME21Mlg5QTR6IN88US=> NEfWUXlUSU6JRWK=
TCCSUP NYrsd|JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTVwOUOyOVkh|ryP NGjrVodUSU6JRWK=
C2BBe1 NGftfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXJXmN{UUN3ME21Mlk{QTdizszN MW\TRW5ITVJ?
TE-15 NXL4WplsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrucmFKSzVyPU[uNFY3ODVizszN NUDScnlXW0GQR1XS
SCLC-21H MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXhTJV1UUN3ME22MlExQDR|IN88US=> MkXHV2FPT0WU
EoL-1-cell NILJbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\ye5hKSzVyPU[uNVY2PjNizszN M4m1d3NCVkeHUh?=
NKM-1 NFj5R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;pTWM2OD14LkG2O|Eh|ryP NE\zfWVUSU6JRWK=
NCI-H1304 NHi0[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD0TWM2OD14LkK3OFI5KM7:TR?= MmrGV2FPT0WU
NB6 MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTZwMkm2NlIh|ryP NHzl[4hUSU6JRWK=
NALM-6 M1;KSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv4TWM2OD14LkOzNlMh|ryP M3nPeXNCVkeHUh?=
NCI-H522 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfNUplKSzVyPU[uN|M{ODZizszN NXjkdJN[W0GQR1XS
MV-4-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf2TWM2OD14LkO3NFc6KM7:TR?= Mny1V2FPT0WU
LB2241-RCC MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPYZmZKSzVyPU[uN|g3PjdizszN MWTTRW5ITVJ?
NCI-H1417 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4njc2lEPTB;Nj60NFg1PyEQvF2= M1XzVnNCVkeHUh?=
HT-1197 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17jb2lEPTB;Nj61O|EzOiEQvF2= NF3BVIlUSU6JRWK=
P30-OHK MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm1epI1UUN3ME22MlYzPzdizszN MYjTRW5ITVJ?
ALL-PO NX;vT4pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO0dJp7UUN3ME22MlcyQTF4IN88US=> NUXqeHR1W0GQR1XS
OVCAR-4 M4DDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nITGlEPTB;Nj63OVQxPSEQvF2= Ml;HV2FPT0WU
HCC2157 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmyXVltUUN3ME22Mlc4PDd3IN88US=> MX7TRW5ITVJ?
NCI-H838 M2jic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HYVWlEPTB;Nj65OlQ6KM7:TR?= NUewUZpuW0GQR1XS
NCI-H1299 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonaTWM2OD14Lkm3NFkh|ryP NEDk[VdUSU6JRWK=
SW954 NWS5bHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTdwMkCwOlgh|ryP M3n0O3NCVkeHUh?=
NCI-H441 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjod2p[UUN3ME23MlM1ODZ3IN88US=> MnfqV2FPT0WU
SK-MEL-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTdwNEizO|Mh|ryP MXLTRW5ITVJ?
KARPAS-45 NGDqbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTdwNkW5Nlkh|ryP M4T1SnNCVkeHUh?=
CAL-54 NVHQNnAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;4UmlEPTB;Nz64Nlk4PyEQvF2= MY\TRW5ITVJ?
KYSE-180 M3;6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTdwOEi5OFEh|ryP MXLTRW5ITVJ?
NCI-H187 NXr2OnZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfWVJFKSzVyPUeuPVU6PDdizszN MVTTRW5ITVJ?
RT-112 M3PFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYriRlRoUUN3ME24MlA6Pjd5IN88US=> MlG3V2FPT0WU
NCI-H1437 M2Hme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ZeFVKSzVyPUiuNFk4QTVizszN MmLFV2FPT0WU
SNU-449 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\NTWM2OD16LkK4NlczKM7:TR?= NETPd|ZUSU6JRWK=
HCC1187 NVvr[ZhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknMTWM2OD16LkK5N|kyKM7:TR?= MVPTRW5ITVJ?
NCI-H2030 NVHUZZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPSTWM2OD16LkO3O|E1KM7:TR?= MV3TRW5ITVJ?
HuO-3N1 MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLLWVQ4UUN3ME24MlM4QDR2IN88US=> MYXTRW5ITVJ?
COLO-792 NHrZeZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRThwNEG1Nlch|ryP NVfxWYtUW0GQR1XS
MIA-PaCa-2 M3;1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRThwOEW1NFgh|ryP MWTTRW5ITVJ?
SK-N-FI M1Swemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHPWodEUUN3ME25MlA1OjVizszN Mny0V2FPT0WU
MMAC-SF NGPCZZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPOfpNKSzVyPUmuNFk4PTFizszN M{D0dnNCVkeHUh?=
NCI-H28 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;DN3gxUUN3ME25MlExPDZ7IN88US=> MXTTRW5ITVJ?
ETK-1 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTlwMkm5O|Qh|ryP MlPFV2FPT0WU
NCI-H1993 NGL5SZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3xWlU1UUN3ME25MlQ1OjZzIN88US=> M2jpXHNCVkeHUh?=
no-11 M2LYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LTR2lEPTB;OT60O|EzKM7:TR?= NFH1eY9USU6JRWK=
ChaGo-K-1 M{f1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTlwNUG1PFMh|ryP NYXWU2ZoW0GQR1XS
NCCIT NW[wNGQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Oze2lEPTB;OT61N|E3QSEQvF2= NIjucIpUSU6JRWK=
SAS NYPVSVFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfYSYd7UUN3ME2xNE4zPDhizszN MWHTRW5ITVJ?
A673 MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFyLkO3NFQh|ryP M325VnNCVkeHUh?=
NCI-H1522 M4DKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TrUWlEPTB;MUCuN|cxPyEQvF2= MWDTRW5ITVJ?
NCI-H810 M3TkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HXfWlEPTB;MUCuN|kxPyEQvF2= M2WzNHNCVkeHUh?=
IST-MES1 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm0TWM2OD1zMD60OVY1KM7:TR?= MYnTRW5ITVJ?
GR-ST NYDMRnJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnjTWM2OD1zMD61NFI1KM7:TR?= NHTpZW5USU6JRWK=
SUP-T1 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H2eGlEPTB;MUCuO|MyPyEQvF2= NXHudJJzW0GQR1XS
NB5 NYPEfWltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DWd2lEPTB;MUCuPVAzOiEQvF2= NGPmVItUSU6JRWK=
MZ1-PC M2jlfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVK2OVZVUUN3ME2xNE46PTdzIN88US=> NXzKbYI{W0GQR1XS
SK-CO-1 M3fhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\UTFJKSzVyPUGwMlk6OzFizszN MUTTRW5ITVJ?
Capan-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnifIVKSzVyPUGxMlMyQThizszN M1P4bnNCVkeHUh?=
697 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hy[mlEPTB;MUGuOlc2PyEQvF2= MVPTRW5ITVJ?
REH M1KzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m1WWlEPTB;MUGuO|Q2OSEQvF2= MVvTRW5ITVJ?
GI-1 NXuwS5RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzaUJBlUUN3ME2xNU45PjF3IN88US=> MlvwV2FPT0WU
BB65-RCC MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnYTWM2OD1zMj6wPVE3KM7:TR?= MVTTRW5ITVJ?
NCI-H1651 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnBTWM2OD1zMj6yOFc5KM7:TR?= NFnsZllUSU6JRWK=
NCI-H1618 NGjsVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGyUVdKSzVyPUGyMlM6PzZizszN MnHHV2FPT0WU
NCI-H2081 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfnT4FKSzVyPUGyMlYyPDFizszN NWjKU4pOW0GQR1XS
GCIY M1;0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF{LkeyNVMh|ryP MorlV2FPT0WU
NY M3XD[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknUTWM2OD1zMz6wOlQ{KM7:TR?= NH;2W|NUSU6JRWK=
PANC-03-27 NWjVPYZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;OcY5uUUN3ME2xN{4xQDB5IN88US=> M{\VPXNCVkeHUh?=
BHY MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz6VJZKSzVyPUGzMlIyOjFizszN M{HNTHNCVkeHUh?=
SK-OV-3 NVrUWphtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF|LkO3OlMh|ryP MUTTRW5ITVJ?
5637 NYnmXXc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;WdGlEPTB;MUOuO|c2QSEQvF2= NUjicHNYW0GQR1XS
LC-1F MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF2LkCzOVYh|ryP M3jOWHNCVkeHUh?=
SNB75 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDLTWM2OD1zND6wN|g{KM7:TR?= NFXwNI5USU6JRWK=
CHP-212 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PEVmlEPTB;MUSuNFQ3PCEQvF2= NULV[|lbW0GQR1XS
HT-1376 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HYV2lEPTB;MUSuNVEzPiEQvF2= M37jNHNCVkeHUh?=
MONO-MAC-6 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF2LkG1NFIh|ryP MnOyV2FPT0WU
CA46 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF2LkG4Nlch|ryP M3;MXXNCVkeHUh?=
SCC-15 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiyfmFKSzVyPUG0MlU2QDNizszN MnfXV2FPT0WU
ATN-1 NUX4TWw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\KTWM2OD1zND62OlI4KM7:TR?= MXPTRW5ITVJ?
NCI-H2405 NHnrT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTITWM2OD1zND64NVU4KM7:TR?= M1\W[HNCVkeHUh?=
NCI-H716 NYHaT|dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTJTWM2OD1zND64OFk{KM7:TR?= M2DOPXNCVkeHUh?=
SW620 NF;jPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vJU2lEPTB;MUSuPVAyPCEQvF2= Mni0V2FPT0WU
NCI-H226 NHT1XVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLJ[XFQUUN3ME2xOE46ODh3IN88US=> NYPJb2FTW0GQR1XS
SW962 NGrrTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\tRVdKSzVyPUG0Mlk1OzJizszN MYXTRW5ITVJ?
KYSE-150 MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3iTWM2OD1zND65OVUh|ryP NHnITnRUSU6JRWK=
OCUB-M NIPaZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXVTWM2OD1zND65PFg{KM7:TR?= M2XMVHNCVkeHUh?=
ES7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjJPZhQUUN3ME2xOU4xQTh2IN88US=> M4PlT3NCVkeHUh?=
SW1463 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37nWGlEPTB;MUWuOFIzOyEQvF2= MV\TRW5ITVJ?
CAKI-1 M4\3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLxRZhyUUN3ME2xOU42OzR4IN88US=> MWjTRW5ITVJ?
MKN28 NELTb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH4cYFKSzVyPUG1MlU1PzlizszN NYW2R|ZQW0GQR1XS
SW13 NV3oV4JDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XneWlEPTB;MUWuOlE5KM7:TR?= MoXIV2FPT0WU
A3-KAW NXnSeZBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHs[nJwUUN3ME2xOU46Pjl5IN88US=> M3HidnNCVkeHUh?=
LU-65 NGfHWWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF3Lkm3Olgh|ryP NHixNlVUSU6JRWK=
Calu-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnT[Fl4UUN3ME2xOk4xOzZ6IN88US=> NWXqUIZnW0GQR1XS
ST486 M{izS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTF4LkC0N|Eh|ryP M{OyVHNCVkeHUh?=
BB30-HNC NVPEPWNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHXTWM2OD1zNj6xNlQ3KM7:TR?= MoXRV2FPT0WU
EGI-1 NGXVSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOzTWM2OD1zNj60OFYh|ryP NX7TdmhHW0GQR1XS
SH-4 MmPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe2TWM2OD1zNj60O|MyKM7:TR?= MYrTRW5ITVJ?
MN-60 NYXnWJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnflTWM2OD1zNz6yNlk4KM7:TR?= MUjTRW5ITVJ?
MPP-89 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTacIFzUUN3ME2xO{4zPDV7IN88US=> Ml\DV2FPT0WU
A2780 NIHTOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7YTWM2OD1zNz60NVM6KM7:TR?= MlrqV2FPT0WU
Daoy NVz5TWlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDkeXRmUUN3ME2xO{41Pjl3IN88US=> M2KxbXNCVkeHUh?=
NCI-H2126 NWTye|FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTFTWM2OD1zNz60O|cyKM7:TR?= MnvVV2FPT0WU
NCI-H1563 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF5LkS5NVch|ryP M{fvbXNCVkeHUh?=
8-MG-BA NXHFNVNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fqUGlEPTB;MUeuOlY1QCEQvF2= MoTIV2FPT0WU
786-0 NV35eI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF5LkizOVMh|ryP M17MZnNCVkeHUh?=
AM-38 NU\vbldlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF5LkmzNFYh|ryP M3H1NnNCVkeHUh?=
COLO-824 NHHFT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfmfFVRUUN3ME2xPE41PDN4IN88US=> MoXqV2FPT0WU
SK-MEL-30 NXrJ[4lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLSTWM2OD1zOD61NFgzKM7:TR?= MYLTRW5ITVJ?
CESS M{Tp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe0TWM2OD1zOD63OlA6KM7:TR?= MmDDV2FPT0WU
BL-70 NYf2SnZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvSSI95UUN3ME2xPE45OTV4IN88US=> NX7pO5RKW0GQR1XS
NCI-H2170 M2PUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF6LkmxO|kh|ryP M1jZWnNCVkeHUh?=
HT-3 MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fKTmlEPTB;MUiuPVg{KM7:TR?= M3;sOHNCVkeHUh?=
BOKU NXvSU3VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXyTWM2OD1zOT6wN|gyKM7:TR?= NVfYcm93W0GQR1XS
HPAF-II M3HPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF7LkOwNVUh|ryP NH;PNYZUSU6JRWK=
KGN MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF7LkS3OlUh|ryP NV;iPYM2W0GQR1XS
MC-CAR MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ESIduUUN3ME2xPU43OzF|IN88US=> NFzn[2RUSU6JRWK=
BHT-101 NV7wbIloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDYU5ZlUUN3ME2xPU44PzdizszN NF7HR5pUSU6JRWK=
SW1783 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rYNWlEPTB;MUmuO|gxPiEQvF2= MWrTRW5ITVJ?
KP-N-YN M4TSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\aTWM2OD1{MD6wNlYzKM7:TR?= MkjTV2FPT0WU
LU-165 NWCxclhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16yR2lEPTB;MkCuOVU4OSEQvF2= NUHkcWhyW0GQR1XS
GOTO MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJyLk[0OVEh|ryP MnnqV2FPT0WU
EFM-19 Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfPTWM2OD1{MT6wO|E3KM7:TR?= NUfCeGlzW0GQR1XS
CTV-1 M2r2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJzLkGwOVQh|ryP MmnyV2FPT0WU
HEL Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJzLkSyNVYh|ryP M4\TUHNCVkeHUh?=
SNU-C2B MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPPNolsUUN3ME2yNU41OjZizszN MYLTRW5ITVJ?
ECC4 M373TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHznPFFKSzVyPUKxMlcxPyEQvF2= MoXRV2FPT0WU
NEC8 NGK3ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTBTHp[UUN3ME2yNU45OzZ6IN88US=> MY\TRW5ITVJ?
KMOE-2 NHfqdo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPkTWM2OD1{MT64PVIyKM7:TR?= NX3ze4EzW0GQR1XS
NCI-H524 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ{LkC4NFgh|ryP M2fWXHNCVkeHUh?=
WSU-NHL M2fYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K1fGlEPTB;MkKuNVU4PyEQvF2= NX7hXFZJW0GQR1XS
SF126 NVnuXopCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvU[VRUUUN3ME2yNk4zPDZ7IN88US=> M1e0V3NCVkeHUh?=
HOP-92 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHTTWM2OD1{Mj6zNVY4KM7:TR?= NXi4NGJyW0GQR1XS
CTB-1 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS1[2I5UUN3ME2yNk41Pjd5IN88US=> NVTHOmZtW0GQR1XS
KYSE-270 M2f3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLQTWM2OD1{Mj65N|U4KM7:TR?= MX;TRW5ITVJ?
SK-MEL-24 NYXndXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTHS3pKSzVyPUKzMlE5PyEQvF2= NX\oU4pGW0GQR1XS
Calu-3 NFi1W41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\FVIxKUUN3ME2yN{4zOTJ6IN88US=> MVzTRW5ITVJ?
GAMG M3W3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnoTWM2OD1{Mz6yN|Y4KM7:TR?= M4fqeHNCVkeHUh?=
SW1573 MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HTV2lEPTB;MkOuO|QyPSEQvF2= MoqxV2FPT0WU
MHH-NB-11 M1zPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ2LkCxPVQh|ryP NU[2[FFuW0GQR1XS
TK10 NGjDRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ2LkWwNVMh|ryP NGLaW4JUSU6JRWK=
LB373-MEL-D NILwTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTCVndtUUN3ME2yOE43ODZ2IN88US=> MoXTV2FPT0WU
KALS-1 NXvSbppwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\Yc2NYUUN3ME2yOE44OzJ5IN88US=> MnvvV2FPT0WU
HUTU-80 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXYTWM2OD1{NT64NFMzKM7:TR?= NFjDNmhUSU6JRWK=
HuP-T3 NYLzTlZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ4LkG2O|Qh|ryP MWjTRW5ITVJ?
OE19 M1PzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDveJdKSzVyPUK2MlIyPTNizszN MkfYV2FPT0WU
J82 MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ4LkK0O|Eh|ryP MUfTRW5ITVJ?
DU-4475 NX\pW3I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jiWGlEPTB;Mk[uN|gyQSEQvF2= MVTTRW5ITVJ?
DMS-53 NFm2WoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ4LkWxN|gh|ryP M3TiXnNCVkeHUh?=
COLO-741 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLITWM2OD1{Nj64N|Q1KM7:TR?= M1\XUHNCVkeHUh?=
SW48 M3jjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ4Lki4NkDPxE1? NGroRphUSU6JRWK=
IGR-1 M{jyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnHVGlKSzVyPUK2Mlk{OzRizszN MWjTRW5ITVJ?
639-V MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknjTWM2OD1{Nz6wNlQ2KM7:TR?= NVnHOoFXW0GQR1XS
LK-2 M1TMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2iwfGlEPTB;MkeuOFE1OSEQvF2= MkPRV2FPT0WU
NCI-H2347 NX3nXY86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXxTWM2OD1{Nz65Olk6KM7:TR?= M{TkUHNCVkeHUh?=
NCI-H2228 NV74XJdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnrSYtCUUN3ME2yPE4xQTB3IN88US=> NIXacHFUSU6JRWK=
LS-123 NFniWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfLO4dKSzVyPUK4MlEzPjJizszN NEXoSYNUSU6JRWK=
U031 M2K4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJ6LkK1NkDPxE1? Mk[zV2FPT0WU
NCI-H1792 NVLzSW1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfETWM2OD1{OD60O|IyKM7:TR?= NULkT4t5W0GQR1XS
NCI-H2087 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KyW2lEPTB;MkiuO|U2OiEQvF2= MVPTRW5ITVJ?
NCI-H2342 NUTGS2N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofETWM2OD1{OT61NlA5KM7:TR?= MX;TRW5ITVJ?
SW626 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW2R2pKSzVyPUK5Mlc2PiEQvF2= Mn;aV2FPT0WU
LB2518-MEL M1uxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnUXnFnUUN3ME2yPU45OTVizszN NVXlNmRkW0GQR1XS
RXF393 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTNyLkC5OVIh|ryP Mn[4V2FPT0WU
LC4-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPRTWM2OD1|MD6zNFkzKM7:TR?= NWLFeItIW0GQR1XS
NCI-H1694 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTNyLk[2NlQh|ryP NHnI[W5USU6JRWK=
K5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\2TFlLUUN3ME2zNE46PzB{IN88US=> M1e4bHNCVkeHUh?=
HDLM-2 M2TKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Toc2lEPTB;M{CuPVczPSEQvF2= NWjoSo51W0GQR1XS
BCPAP NFzINGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnMW2pKSzVyPUOxMlg{PzlizszN NXnUOIptW0GQR1XS
BC-3 M2\l[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjM[HBFUUN3ME2zNk4yPDB|IN88US=> MVrTRW5ITVJ?
LB996-RCC M1nIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq0cVdLUUN3ME2zNk4zOzV6IN88US=> M4PvV3NCVkeHUh?=
NCI-H2009 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e0[2lEPTB;M{KuOFk5OSEQvF2= NUDabXloW0GQR1XS
HTC-C3 NX;SOlViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLheGtKSzVyPUOzMlc2OTlizszN MVLTRW5ITVJ?
LAMA-84 NHzRTWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorITWM2OD1|ND60OFA4KM7:TR?= M172XHNCVkeHUh?=
CCRF-CEM MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LmVGlEPTB;M{SuOVcyPSEQvF2= Ml3rV2FPT0WU
AN3-CA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHPTWM2OD1|NT6wOVY5KM7:TR?= NV22VVlsW0GQR1XS
NCI-H1734 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEn6WWxKSzVyPUO1MlI2PjFizszN MVrTRW5ITVJ?
Ca-Ski MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHV[4FpUUN3ME2zOU41OTBzIN88US=> MmnTV2FPT0WU
U-266 NX:xUFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTN3Lk[xNVQh|ryP NVT5ZoxSW0GQR1XS
SBC-5 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDsUmtKSzVyPUO1Mlc4QDFizszN M2i1ZnNCVkeHUh?=
GT3TKB NH\zSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn4WmVKSzVyPUO3MlEyPSEQvF2= MV;TRW5ITVJ?
MDA-MB-175-VII M1PTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\IcoIyUUN3ME2zO{4zOjR6IN88US=> MX3TRW5ITVJ?
PFSK-1 NHHGOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rDbWlEPTB;M{euNlQ{PSEQvF2= NHy0WmdUSU6JRWK=
IMR-5 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO2fW9{UUN3ME2zO{4zPDh5IN88US=> NEf4TplUSU6JRWK=
Daudi NFLYfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rCWmlEPTB;M{euN|U6PyEQvF2= NH7hRpdUSU6JRWK=
A498 M3jkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DLWGlEPTB;M{euO|IyQCEQvF2= Mn\SV2FPT0WU
SCC-4 M{jqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHXTWM2OD1|Nz63PFQ{KM7:TR?= M3\Gb3NCVkeHUh?=
COLO-680N NUDCN3hUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zGXWlEPTB;M{iuNlg5PSEQvF2= MmTUV2FPT0WU
SK-MES-1 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTN6LkOyNVUh|ryP M4fpb3NCVkeHUh?=
SR NGHEUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN6LkW0PVUh|ryP NHrrZ2RUSU6JRWK=
LNCaP-Clone-FGC NUD6So1[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13mR2lEPTB;M{iuOVY{PyEQvF2= NWXOVJJKW0GQR1XS
SK-HEP-1 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN6Lke4NlIh|ryP M1jrN3NCVkeHUh?=
BPH-1 NHXtVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTN6LkizNlkh|ryP M4j3VXNCVkeHUh?=
NCI-H1755 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK2eWdKSzVyPUO5MlU5OTdizszN NE\hdXhUSU6JRWK=
LXF-289 NEW3OWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPUVllKSzVyPUO5MlgxQDRizszN NFXwdnBUSU6JRWK=
SW1088 NXnxb2FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTRyLkKxNFch|ryP NHjiWJFUSU6JRWK=
MOLT-4 NFTHNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPHTWM2OD12MD6yPVAyKM7:TR?= NUTmXXdGW0GQR1XS
AsPC-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG1TWM2OD12MD60OVg{KM7:TR?= Mln6V2FPT0WU
HOP-62 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTRyLk[1Olgh|ryP MWnTRW5ITVJ?
A172 NH3pdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULncFhzUUN3ME20NE45PTFzIN88US=> NYHwNFY{W0GQR1XS
SN12C MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3IOnBKSzVyPUSwMlk{QDVizszN MkL4V2FPT0WU
MDA-MB-231 NIfVbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvOb3FKSzVyPUSwMlk5QThizszN NEm2NW9USU6JRWK=
RPMI-2650 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTRzLkG1PVMh|ryP NUiyTpV7W0GQR1XS
KYSE-140 M2ju[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Xr[GlEPTB;NEGuPFEzOyEQvF2= M2DHWHNCVkeHUh?=
KINGS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDiVVRwUUN3ME20Nk41Pjl5IN88US=> MV\TRW5ITVJ?
HSC-3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTR{Lk[2OlEh|ryP Mli0V2FPT0WU
PC-14 MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;QTWM2OD12Mz6xPFgzKM7:TR?= MVHTRW5ITVJ?
COR-L105 NHrOT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnZTWM2OD12Mz62OVAzKM7:TR?= M1Thd3NCVkeHUh?=
BE-13 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR2LkKzO|Eh|ryP NG\6Z2VUSU6JRWK=
NCI-H661 M17YS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[0XZhKSzVyPUS0MlI6PThizszN MVfTRW5ITVJ?
IST-MEL1 NY\ZeoY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK3W4NKSzVyPUS0MlM2QTlizszN NF;tUGlUSU6JRWK=
HCC1806 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTR2LkW4O|Mh|ryP M4jadXNCVkeHUh?=
COLO-800 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPZeY9KSzVyPUS0Mlg1PTNizszN NH3kbZNUSU6JRWK=
IST-SL2 MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTR3LkGyOFch|ryP NX\Ic3ZvW0GQR1XS
8305C NUH1[FE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDDTWM2OD12NT6zNFkh|ryP MVLTRW5ITVJ?
UACC-62 NFrCWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTnTWM2OD12Nj6yPFc2KM7:TR?= NVXSS|BtW0GQR1XS
COR-L23 M4\uO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLrTWM2OD12Nz6xPVkh|ryP NY\yfYQzW0GQR1XS
EFE-184 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqx[oFKSzVyPUS3MlM5QCEQvF2= MUTTRW5ITVJ?
DMS-114 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX6TWM2OD12Nz60NVQ6KM7:TR?= NVLaRmh{W0GQR1XS
KYSE-520 MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXHTWM2OD12OD61N|E2KM7:TR?= Mki4V2FPT0WU
SNG-M MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTR7LkSzOEDPxE1? MXnTRW5ITVJ?
A2058 NXjLZnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TLdGlEPTB;NEmuOFg5PSEQvF2= NHfpTpdUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
細胞試験: [1]
+ 展開
  • 細胞株: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • 濃度: 0.02-0.8 μM
  • 反応時間: 3 days
  • 実験の流れ: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • 製剤: 25 mM tartaric acid
  • 投薬量: 25 mg / kg and 75 mg / kg
  • 投与方法: Orally administrated at once-daily oral dose for 14 days
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R信号経路図

IGF-1R Inhibitors with Unique Features

相関IGF-1R製品

Tags: Linsitinib (OSI-906)を買う | Linsitinib (OSI-906) ic50 | Linsitinib (OSI-906)供給者 | Linsitinib (OSI-906)を購入する | Linsitinib (OSI-906)費用 | Linsitinib (OSI-906)生産者 | オーダーLinsitinib (OSI-906) | Linsitinib (OSI-906)化学構造 | Linsitinib (OSI-906)分子量 | Linsitinib (OSI-906)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID